Get the Stockscreener App
15.17
3.07%
-0.48
After Hours:
14.84
-0.33
-2.18%
Adaptive Biotechnologies Corp stock is traded at $15.17, with a volume of 976.97K.
It is down -3.07% in the last 24 hours and up +22.14% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$15.65
Open:
$15.79
24h Volume:
976.97K
Relative Volume:
0.50
Market Cap:
$2.31B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-11.32
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
+5.49%
1M Performance:
+22.14%
6M Performance:
+96.38%
1Y Performance:
+208.96%
1-Day Range:
$15.13
$15.83
1-Week Range:
$14.11
$15.83
52-Week Range:
$4.27
$15.83
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.17 | 2.38B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Is Adaptive Biotechnologies Corporation stock near bottom after declineEarnings Recap Report & Free High Return Stock Watch Alerts - newser.com
Adaptive Biotechnologies Corp. Hits New 52-Week High of $15.57 - Markets Mojo
Adaptive Biotechnologies Hits Day High with 8.36% Surge in Stock Price - Markets Mojo
Risk vs reward if holding onto Adaptive Biotechnologies CorporationLong Setup & Risk Controlled Daily Trade Plans - newser.com
Will Adaptive Biotechnologies Corporation bounce back from current support2025 Short Interest & Target Return Focused Stock Picks - newser.com
Adaptive Biotechnologies stock hits 52-week high at $15.29 By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies stock hits 52-week high at $15.29 - Investing.com
Adaptive Biotechnologies (ADPT): A Fresh Analyst Spotlight Prompts a Closer Look at Valuation and Growth Potential - simplywall.st
What technical signals suggest for Adaptive Biotechnologies Corporation stockJuly 2025 Analyst Calls & Intraday High Probability Setup Alerts - newser.com
Can volume confirm reversal in Adaptive Biotechnologies CorporationJuly 2025 Selloffs & Weekly Momentum Picks - newser.com
Why analysts upgrade Adaptive Biotechnologies Corporation stock2025 Biggest Moves & Low Risk High Win Rate Picks - newser.com
Is Adaptive Biotechnologies Corporation (1HM) stock bottoming after sell offJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Adaptive Biotechnologies Corporation trending in predictive chart modelsQuarterly Risk Review & Free Weekly Watchlist of Top Performers - newser.com
What recovery options are there for Adaptive Biotechnologies CorporationJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Why Adaptive Biotechnologies (ADPT) Is Up 8.5% After clonoSEQ’s Integration With Flatiron Health’s OncoEMR - simplywall.st
Is Adaptive Biotechnologies Corporation stock poised for growthJuly 2025 Earnings & Reliable Trade Execution Plans - newser.com
Adaptive Biotechnologies Corporation stock momentum explainedJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Adaptive Biotechnologies Corp. Hits New 52-Week High of $15.26 - Markets Mojo
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Adaptive Biotechnologies Corp. Hits New 52-Week High at $15.04 - Markets Mojo
Adaptive Biotechnologies Hits Day High with 13.94% Surge in Stock Price - Markets Mojo
Adaptive Biotechnologies stock hits 52-week high at $14.49 By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Now Covered by Analysts at Guggenheim - Defense World
A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts - Benzinga
Guggenheim Initiates Coverage on ADPT with 'Buy' Rating | ADPT S - GuruFocus
Adaptive Biotechnologies stock hits 52-week high at $14.49 - Investing.com
Guggenheim Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Will Adaptive Biotechnologies Corporation (1HM) stock gain from lower interest ratesWeekly Investment Summary & Free Real-Time Volume Trigger Notifications - newser.com
Real time alert setup for Adaptive Biotechnologies Corporation performanceWeekly Risk Summary & Step-by-Step Trade Execution Guides - newser.com
Is Adaptive Biotechnologies Corporation (1HM) stock dividend growth reliableCEO Change & Entry Point Strategy Guides - newser.com
Adaptive Biotechnologies Corporation stock outlook for YEARSwing Trade & Safe Swing Trade Setups - newser.com
The Bull Case For Adaptive Biotechnologies (ADPT) Could Change Following Analyst Upgraded Earnings Outlook - Yahoo Finance
Adaptive Biotechnologies (ADPT): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? - Yahoo Finance
Adaptive Biotechnologies Stock Hits Day Low of $12.72 Amid Price Pressure - Markets Mojo
Adaptive Biotechnologies Corp. Hits New 52-Week High at $14.27 - Markets Mojo
Adaptive Biotechnologies Corp. Hits New 52-Week High of $14.47 - Markets Mojo
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt? - simplywall.st
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptive Biotechnologies Corp Stock (ADPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROBINS HARLAN S | Chief Scientific Officer |
May 01 '25 |
Option Exercise |
6.32 |
68,412 |
432,364 |
1,347,936 |
| ROBINS HARLAN S | Chief Scientific Officer |
May 01 '25 |
Sale |
7.35 |
68,412 |
502,828 |
1,279,524 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):